Impact BioMedical, Inc. (IBO) - Net Assets
Based on the latest financial reports, Impact BioMedical, Inc. (IBO) has net assets worth $-8.85 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.21 Million) and total liabilities ($27.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Impact BioMedical, Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.85 Million |
| % of Total Assets | -48.62% |
| Annual Growth Rate | 43.61% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 372.23 |
Impact BioMedical, Inc. - Net Assets Trend (2016–2024)
This chart illustrates how Impact BioMedical, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Impact BioMedical, Inc. (IBO) total assets for the complete picture of this company's asset base.
Annual Net Assets for Impact BioMedical, Inc. (2016–2024)
The table below shows the annual net assets of Impact BioMedical, Inc. from 2016 to 2024. For live valuation and market cap data, see market cap of Impact BioMedical, Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.24 Million | -74.39% |
| 2023-12-31 | $28.26 Million | -13.49% |
| 2022-12-31 | $32.67 Million | +1009.72% |
| 2021-12-31 | $2.94 Million | +55824.13% |
| 2020-12-31 | $-5.28K | -105.57% |
| 2019-12-31 | $94.89K | -51.86% |
| 2018-12-31 | $197.12K | -33.23% |
| 2017-12-31 | $295.22K | -26.19% |
| 2016-12-31 | $400.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Impact BioMedical, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3766900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.26% |
| Other Components | $41.92 Million | 984.20% |
| Total Equity | $4.26 Million | 100.00% |
Impact BioMedical, Inc. Competitors by Market Cap
The table below lists competitors of Impact BioMedical, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Haranga Resources Ltd
AU:HAR
|
$45.61 Million |
|
Demire Deutsche Mittelstand Real Estate AG
F:DMRE
|
$45.64 Million |
|
Auric Mining Ltd
AU:AWJ
|
$45.64 Million |
|
Korea Refract
KO:010040
|
$45.65 Million |
|
Baltic Sea Properties AS
OL:BALT
|
$45.54 Million |
|
Panorama Sentrawisata Tbk
JK:PANR
|
$45.53 Million |
|
European Metals Holdings Ltd
AU:EMH
|
$45.50 Million |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
$45.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Impact BioMedical, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 25,222,000 to 4,259,000, a change of -20,963,000 (-83.1%).
- Net loss of 2,051,587 reduced equity.
- Share repurchases of 3,726,000 reduced equity.
- New share issuances of 3,726,000 increased equity.
- Other factors decreased equity by 18,911,413.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.05 Million | -48.17% |
| Share Repurchases | $3.73 Million | -87.49% |
| Share Issuances | $3.73 Million | +87.49% |
| Other Changes | $-18.91 Million | -444.03% |
| Total Change | $- | -83.11% |
Book Value vs Market Value Analysis
This analysis compares Impact BioMedical, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.05x to 4.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.03 | $0.44 | x |
| 2018-12-31 | $0.02 | $0.44 | x |
| 2019-12-31 | $0.01 | $0.44 | x |
| 2020-12-31 | $-0.07 | $0.44 | x |
| 2021-12-31 | $0.02 | $0.44 | x |
| 2022-12-31 | $2.57 | $0.44 | x |
| 2023-12-31 | $0.13 | $0.44 | x |
| 2024-12-31 | $0.10 | $0.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Impact BioMedical, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -48.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -88.01%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 4.76x
- Recent ROE (-48.17%) is above the historical average (-128.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -138.30% | 0.00% | 0.00x | 1.09x | $-437.81K |
| 2018 | -49.77% | 0.00% | 0.00x | 1.10x | $-117.82K |
| 2019 | -621.85% | 0.00% | 0.00x | 1.23x | $-599.57K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-759.54K |
| 2021 | -131.36% | -7734.43% | 0.01x | 1.36x | $-4.16 Million |
| 2022 | -23.85% | -14102.00% | 0.00x | 1.57x | $-10.01 Million |
| 2023 | -17.19% | -420.98% | 0.02x | 1.77x | $-6.86 Million |
| 2024 | -48.17% | -88.01% | 0.11x | 4.76x | $-2.48 Million |
Industry Comparison
This section compares Impact BioMedical, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $190,806,965
- Average return on equity (ROE) among peers: -24.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Impact BioMedical, Inc. (IBO) | $-8.85 Million | -138.30% | N/A | $45.54 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.45 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $67.72 Million | -21.45% | 0.18x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $184.86 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $196.01 Million | -75.37% | 0.67x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $309.49 Million | -29.88% | 0.05x | $3.82 Billion |
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more